DUPs Brexit ads: Who bankrolled the secretive 435,000 campaign? – The Irish Times

Longford-born journalist Peter Geoghegan was sitting in a train carriage in Newcastle just before the Brexit referendum in 2016 when a quest began to unravel a mystery about the Democratic Unionist Partys role in winning it.

Flicking through a well-thumbed copy of the Metro newspaper, Geoghegan, who works now in Glasgow and London, saw the free newspapers front page wraparound advertisement.

In it, British voters were urged to Take back control, the slogan of the official Vote Leave campaign, Geoghegan recalls in his new book, Democracy for Sale, which is published by Head of Zeus on Thursday.

I turned the paper over. An imprint on the back said that the advert had been paid for by the Democratic Unionist Party, says Geoghegan, a journalist with opendemocracy.net.

This was very curious. Since its foundation in 1971, the Democratic Unionist Party had never run a single candidate outside Northern Ireland, he writes.

It was a little epiphany that ultimately led him down a number of other tracks and has resulted in the book.

It is filled with the likes Steve Bannon, Donald Trump, Dominic Cummings, Boris Johnson, Nigel Farage and a former head of Saudi Arabian intelligence, Prince Nawwaf bin Abdul Aziz al Saud.

Right there, too, is the DUP, which spent 435,000 on a massive ad campaign promoting Brexit in England. I knew that election spending in the UK is tightly capped.

I also knew, having worked as a reporter in Belfast, that political donations to Northern Irish parties were kept secret under anachronistic local laws. Perhaps this was a way around campaign limits?

So, would he solve the mystery?

In his sleuthing Geoghegan examines how the DUP was bankrolled by the biggest [political] donation in Northern Irish history to support the campaign to take the UK out of the European Union.

Geoghegan contends in Democracy for Sale that the money was channelled to the DUP through the official Vote Leave campaign because Vote Leave had almost used up its permitted spending of 7 million.

Vote Leave and the DUP have denied the claim.

Other organisations on both sides of the campaign were allowed additional spending of up to 700,000. The author recounts how he discovered that an uncommunicative organisation called the Constitutional Research Council (CRC) donated 435,000 to the DUP to support the Leave crusade.

To prop up his Vote Leave-DUP connection conviction, Geoghegan writes, Two months before the referendum, Matthew Elliott, Vote Leaves chief executive, wrote in an email to senior staff: The DUP also have a 700k spending limit, which can be spent nationwide!

At that stage the DUP had yet to register as a referendum participant, Geoghegan writes. It only did so in late May. When the CRC started giving money to the DUP, Vote Leave had almost completely exhausted its spending allowance.

Geoghegan writes how the DUPs Brexit spending spree began on June 9th, exactly two weeks before the vote, when the DUP bought 100,000 worth of placards, bags, window stickers, T-shirts and badges from a small branding agency called Soopa Doopa.

This company was based in the Cambridgeshire cathedral town of Ely. The location and the company was a surprising choice for the DUP, thought Geoghegan. The fact that it published more than 800,000 of material for various Leave-supporting groups reinforced his belief that this was part of the alleged Vote Leave-DUP nexus.

Two days before polls opened, Geoghegan writes, the CRC donated a further 334,993 to the DUP, much of which was spent on the wraparound ad in the Metro a paper that does not circulate in Northern Ireland.

He also says the DUP spent 32,000 on digital advertising through a Canadian company called AggregateIQ (AIQ) which had bought millions of pounds worth of Facebook ads on behalf of a suite of pro-Brexit campaigns clustered around Vote Leave.

The Westminster fake news inquiry that began in 2017 and concluded in 2019 heard that AIQ had links with Cambridge Analytica, the political consulting firm founded by US billionaire Robert Mercer and US president Donald Trumps former chief strategist Steve Bannon, although this has been denied by AIQ co-founder Zack Massingham.

Cambridge Analytica got in serious trouble over allegedly misappropriating digital information, including acquiring the personal data of tens of millions of Facebook users.

Geoghegan, following the money trail, writes that according to Cambridge Analytica whistleblower Chris Wylie, the DUP were simply a front organisation to allow Vote Leave to go beyond spending limits imposed by election laws again a charge that Vote Leave and the DUP strongly deny.

Geoghegan explores how the only publicly known person associated with the CRC the group that gave the 435,000 to the DUP is Scottish businessman Richard Cook, a Conservative Party activist and Glasgow Rangers supporter.

He is depicted as a colourful figure, who in 2013 jointly founded a company called Five Star Investments with Prince Nawwaf bin Abdul Aziz al Saud, a former director general of the Saudi intelligence agency who died in 2015. Cook held 5 per cent of the shares, the prince 75 per cent, and a third man, Danish national Peter Haestrup, held the other 20 per cent.

Haestrup was allegedly linked to an Indian gun-running case known as the Purulia Arms Drop. Haestrup told Geoghegan he was never charged, had a 100 per cent clean record and had done nothing wrong. He also explained how the wealth management business did not get off the ground and was dissolved in 2014 after a lot of good dinners.

Despite these intriguing connections, Geoghegan portrays Cook as a man who would not have 435,000 to easily hand over to the DUP. He is convinced the CRC money came from other sources. Former Scottish Labour leader Jim Murphy told Geoghegan that Cook, his long-time political adversary in East Renfrewshire, was a bizarrely unlikely middle-man for this sort of money.

In addition to the 435,000, the author writes about how the CRC made two further contributions to the DUP after the Brexit referendum, totalling more than 13,000 the DUP very generally and impenetrably saying it had used the money to further the cause of unionism at home and abroad.

Geoghegan writes that Cook refused to reveal the source of the cash and said that, although he had administered the massive DUP donation, he had never received any money from his involvement in the CRC. I just run a small consultancy company, doing some waste energy stuff internationally, he said.

Geoghegan does a lot of mining to find the other CRC backers but, as he admits, the gold seam proves elusive, his work not helped by electoral law in Northern Ireland or the DUPs refusal to answer questions.

Under previous electoral legislation in the North, political donors during the Troubles did not have to disclose their names or the size of their contributions because doing so could endanger their lives.

In July 2017 that changed when then northern secretary James Brokenshire decided that life had moved on and donation details could be published.

It could have been the moment that changed everything. However, it was not to be. Brokenshire could have backdated that legislation to January 2014, but decided not to.

This led to allegations that he had done a side deal with the DUP a charge bolstered by the fact that this was at a time when the DUP had signed up to a 1.5 billion confidence and supply deal to keep then UK prime minister Theresa Mays Tory government in power.

It prompted former head of the Norths Electoral Commission Seamus Magee to deduce: The deal on party donations and loans must be part of the DUP/Conservative deal. No other explanation.

This was denied at the time by DUP MP Jeffrey Donaldson.

Geoghegan, still chasing, writes how, in mid December 2017, 17 MPs met in a Westminster committee room to consider a legal order that would bring donor transparency to Northern Ireland.

During a truncated and bad-tempered debate, DUP MPs Sammy Wilson and Ian Paisley, who were observers, insisted that their party had been wholly transparent about the 435,000 donation.

Saying that the failure to backdate the legislation stinks, Labour MP Ben Bradshaw added: The only conclusion that any reasonable person can draw is that the DUP was used, with its knowledge, by the CRC to funnel money to the Leave campaign in a way that to this day keeps the source of that money secret. By refusing to make this provision retrospective, the government are effectively complicit in covering that up.

In his book Geoghegan addresses many fascinating issues in relation to dark money, Brexit and political funding but in the end admits his investigation into the DUP and CRC does did not answer the big question.

The wall of silence could not be penetrated. He concedes, Just how much control the DUP had over its record donation and how it was spent remains unclear. And who was behind the money is still a mystery.

View original post here:

DUPs Brexit ads: Who bankrolled the secretive 435,000 campaign? - The Irish Times

Brexit hit looms for industries that escaped worst of pandemic – The London School of Economics and Political Science

Businesses that have escaped the worst effects of the economic fallout from the COVID-19 pandemic are typically in sectors which are more likely to feel the impacts of Brexit, a new analysis finds.

The reportCOVID-19 and Brexit:Real-time updates on business performance in the United Kingdomwas published today (29 July 2020) by the LSEs Centre for Economic Performance (CEP). It shows that sectors which entail more human contact such as airlines, restaurants, hotels and arts and entertainment have been hardest hitby the pandemic.

Meanwhile, those sectors that rely more on business-to-business demand, and which can be delivered virtually, have been less hard hit. These include ICT services and professional, technical and scientific industries such as accounting, legal activities and scientific research.

Report authors, Josh De Lyon and Dr Swati Dhingra,alsoshow that sectors affected by Brexit are generally different to those currently impacted by COVID-19. When comparing the effect of COVID-19 with the predicted impact of increased trade barriers with the EU, there is some evidence that those lesshitby COVID-19 are likely tosuffer more fromBrexit. Electrical and Optical Equipment and Chemicals and Chemical Products are examples of such sectors.

A closer look shows the experiences of industries differs a lot. While businesses such as hotels and restaurants have been hit hard by COVID-19, they are predicted to see little change from trade rules with the EU. Other sectors, however, such as Inland Transport have been impacted by the pandemic and are also expected to be significantly affected by a no-deal Brexit, thus experiencing a double hit.

The analysis uses data from the real-time business survey of member and non-member firms collected by the Confederation of British Industry (CBI). This shows how business performance and expectations have varied in April, May and June 2020.

It reveals:

Josh De Lyon, research assistant at CEP, said:As the impacts of COVID-19 on different types of business become clearer, the government must move beyond its broad assessment of Brexit impacts to much more finely tuned plans that account for the differences in market conditions and constraints faced by UK businesses in the biggest slowdown of our lifetime.

Dr Swati Dhingra, CEP associate and Associate Professor in Economics at LSE, said:The large negative hit from the pandemic has reduced the capacity of the UK economy to take further shocks. The UK is highly integrated with Europe and these links are likely to be even more important throughout the pandemic. The slowdown of the world economy has also cast another shadow on the idea of a Global Britain unlocking a higher trade potential outside of the EU.

Our analysis shows that the sectors that will be affected by Brexit and those that are suffering from the COVID-19 pandemic and lockdown are generally different from each other. Rushing Brexit through this year without a new deal in place would therefore broaden the set of sectors that see worsening business conditions.

The report concludes that government policies to stimulate demand, support workers to remain in employment or find new employment, and to support businesses remain essential.

The full report can be read here:COVID-19 and Brexit: Real-time updates on business performance in the United Kingdom

See the article here:

Brexit hit looms for industries that escaped worst of pandemic - The London School of Economics and Political Science

Government says medicines must be stockpiled for no-deal Brexit on top of Covid-19 pressures – The Independent

The government has written to to medicine suppliers urging them to stockpile drugs for a possible no-deal in EU trade talks at the end of the year after firms warned that this may not be possible because of the pandemic.

In a letter made public on Monday officials at the health department said the government recognises "that global supply chains are under significant pressure" because of coronavirus, but said the expensive precaution was still necessary.

In June a pharmaceutical industry memo said original stockpiles meant for no-deal had been used up entirely and that it might not be possible to replenish them before December, when the UK is due to leave the single market.

Sharing the full story, not just the headlines

Boris Johnson refused to extend the Brexit transition period last month despite disruption caused by coronavirus and the fact the UK is facing a cliff-edge at the end of the year.

Flagging trade talks mean it is increasingly likely that Britain will leave the single market without any trade agreement at all, with disruption to trade and supply chains expected.

"Holding additional stock in the UK provides a further buffer against some disruption and we believe, where its possible, its a valuable part of a robust contingency plan," the letter, signed by Steve Oldfield, chief commercial officer at the Department of Health and Social Cares says.

"To build upon past work and ensure a co-ordinated approach, we will be asking suppliers to confirm their contingency plans for the end of the [transition period], and in particular the balance between stock-holding in the UK, re-routing away from the short straits and readiness for new customs and border arrangements.

"We recognise that global supply chains are under significant pressure, exacerbated by recent events with COVID-19. However, we encourage companies to make stockpiling a key part of contingency plans, and ask industry, where possible, to stockpile to a target level of 6 weeks total stock on UK soil. DHSC stands ready to support companies with their plans if required and understands that a flexible approach to preparedness may be required that considers a mixture of stockpiling and rerouting plans as necessary."

But the memo reported earlier in the year from the pharmaceutical industry warned that there would be less or zero product available in the market to allow for stockpiling a broad range of products thanks to the pandemic.

It continued: We would warn against any drastic policies mandating wholesale changes to global supply chains, as this could fundamentally disrupt the supply of medicines for the NHS and patients in other countries."

Pro-Brexit supporters celebrating in Parliament Square, after the UK left the European Union on 31 January. Ending 47 years of membership

PA

Big Ben, shows the hands at eleven o'clock at night

AFP via Getty

Pro Brexit supporters attend the Brexit Day Celebration Party hosted by Leave Means Leave

Getty

Brexit Party leader Nigel Farage smiles on stage

AFP/Getty

People celebrate in Parliament Square

Reuters

A Brexit supporter celebrates during a rally in Parliament square

AP

Police form a line at Parliament Square to prevent a small group of anti-Brexit protestors from going through to the main Brexit rally

PA

Nigel Farage speaks to pro-Brexit supporters

PA

PA

JD Wetherspoon Chairman Tim Martin speaks as people wave flags

Reuters

Getty

Brexit supporters wave Union flags as they watch the big screen

AFP via Getty

Brexit Party leader, Nigel Farage arrives

Reuters

Brexit supporters gather

AP

Ann Widdecombe speaks to pro-Brexit supporters

PA

Brexit supporters wave Union flags as they watch the big screen

AFP via Getty

AFP via Getty

People wave British Union Jack flags as they celebrate

Reuters

Pro-Brexit demonstrators celebrate on Parliament Square on Brexit day

Reuters

A pro-Brexit supporter jumps on an EU flag

PA

Getty

AFP via Getty

PA

Getty

AP

Getty

A man waves Union flags from a small car as he drives past Brexit supporters gathering

AFP via Getty

A pro-Brexit supporter pours beer onto an EU flag

PA

Getty

An EU flag lies trampled in the mud

Getty

Getty

PA

PA

Getty

Getty

PA

AFP via Getty

Pro-Brexit supporters celebrating in Parliament Square, after the UK left the European Union on 31 January. Ending 47 years of membership

PA

Big Ben, shows the hands at eleven o'clock at night

AFP via Getty

Pro Brexit supporters attend the Brexit Day Celebration Party hosted by Leave Means Leave

Getty

Brexit Party leader Nigel Farage smiles on stage

AFP/Getty

People celebrate in Parliament Square

Reuters

A Brexit supporter celebrates during a rally in Parliament square

AP

Police form a line at Parliament Square to prevent a small group of anti-Brexit protestors from going through to the main Brexit rally

PA

Nigel Farage speaks to pro-Brexit supporters

PA

PA

JD Wetherspoon Chairman Tim Martin speaks as people wave flags

Reuters

Getty

Brexit supporters wave Union flags as they watch the big screen

AFP via Getty

Brexit Party leader, Nigel Farage arrives

Reuters

Brexit supporters gather

AP

Ann Widdecombe speaks to pro-Brexit supporters

PA

Brexit supporters wave Union flags as they watch the big screen

AFP via Getty

AFP via Getty

People wave British Union Jack flags as they celebrate

View post:

Government says medicines must be stockpiled for no-deal Brexit on top of Covid-19 pressures - The Independent

Brexit will deliver double shock to UK economy, study finds – The Guardian

A Brexit hit is looming for sectors that have emerged relatively unscathed from the Covid-19 pandemic, analysis by the London School of Economics suggests.

The LSE report says Brexit will deliver a double shock to the economy with business conditions worsening for those sectors that have survived the impact of coronavirus and lockdown measures whether Boris Johnson secures a deal with the EU or not.

The analysis, seen by the Guardian before its publication on Wednesday, includes information from a monthly survey of Confederation of British Industry members.

Our analysis shows that the sectors that will be affected by Brexit and those that are suffering from the Covid-19 pandemic and lockdown are generally different from each other, said Swati Dhingra, an economics professor who co-authored the report.

A simultaneous impact from Brexit and coronavirus will be felt across the business spectrum from the autumn when the chancellor Rishi Sunaks pandemic policies aimed at supporting the unemployed end and the new trading environment for the UK outside the EU begins to bite, the research finds.

The report, Covid-19 and Brexit: Real-Time Updates on Business Performance in the United Kingdom by the LSEs Centre for Economic Performance, shows sectors that entail more human contact including hospitality, air travel, restaurants, hotels, and arts and entertainment have been the hardest hit by the pandemic.

The affect on other sectors such as the scientific industries, professional services, including accountancy and legal services, and publishing has been less severe because they can continue to operate with staff working from home.

Among those reportedly continuing to operate with remote working are firms such as Vodafone, Google, the accountancy firm KPMG, GlaxoSmithKline, Rolls-Royce and the consumer goods group Unilever.

But Brexit will impose barriers on those trading goods or services with the EU, whether it is pharmaceutical companies seeking regulatory approval, banks or services needing to transfer data from servers in the bloc or car manufacturers or clothes importers being required to fill in customs declarations for the first time in decades.

The report points out that as far back as 2017 the government announced that Brexit would be guided by impact assessments across sectors; it has provided detailed analysis in only 10 sectors to date.

The government must move beyond its broad assessment of Brexit impacts to much more finely tuned plans in preparation for the biggest slowdown of our lifetime said Josh de Lyon, a research assistant at the LSE centre who co-authored the report.

Dhingra said the coronavirus pandemic had reduced the capacity of the UK economy to take further shocks, and rushing Brexit through would broaden the set of sectors that experienced worsening business conditions.

Using monthly data collected by the CBI on business experiences and expectations of growth or declines, along with what it describes as state of the art modelling, the centre has been able to assess the outlook for the next three months.

LSE, like other big institutions, is loath to put a figure on the projected combined shock to the economy although various sectors have warned of hardship coming down the tracks. The manufacturing body Make UK warned that more than half of the manufacturing sector was planning redundancies when the business support schemes ended.

The LSE report urges the government to put in place an industrial strategy that must reflect the cold reality of being in a post-Brexit UK which is placed in a post-Covid world economy in which global trade shrinks.

Read more:

Brexit will deliver double shock to UK economy, study finds - The Guardian

From the C to the B – Putting the B back in Brexit – Finextra

Do you remember when Brexit dominated almost every element of the daily discourse? Every headline, every TV news story, every social media link involved the B-word. Half of all conversations touched upon or outright focussed on the latest B-news. You could barely look a computer, a billboard or dare I say a bus without seeing B-stuff. It was almost a relief when you looked at a news outlet and something dramatic had happened because at least it afforded some slight respite from bloody Brexit!

Then in true Sesame Street fashion, the next episodes of life were brought to us by the letter C and as well as the actual pandemic there was a pandemic of coverage. C-themed stories were everywhere and the deluge of C-topics washed away all those B-stories. Ok, this is not entirely true as there were one or two B-C-stories such as our transition deal membership of the EU keeping UK food supplies moving, the contribution of EU nurses to our heroic NHS frontline and the failure to accept the EUs help with PPE. But Im sailing dangerously close to the political line that business commentators are best avoiding. In an effort to navigate back to safer waters and reinforce my theme, lets just agree that pesky C pushed troublesome B off of the agenda.

Bringing it

Well the good news is that Im bringing back Brexit!

Admittedly, this is probably only good news if you are totally fed up with crummy COVID (almost certainly yes). Are nostalgic for all the Brexit talk (pretty sure youre not). Or involved in banking and wondering how to dispose of that excess budget this year (guess thats probably nope too).

So why do we want to discuss Brexit? Simple. Its the end of July. That simple really. The real question is why arent we discussing Brexit?

Barring a spectacular change in direction (though 2020 so far has taught me not to ruleanything out) this Brexit business happens in 5 short months. The remainder of this article focuses on what that means for regulatory transaction reporting.

The bamboo chopping board of fate

At the 30,000 feet level, there is currently an EU-wide implementation of EMIR, MiFIR and SFTR that covers the 27 EU countries plus the UK. At the stroke of midnight on December 31st the hand of fate takes a meat cleaver and chops each of these three regimes into two very similar, but nonetheless distinct versions. Whilst many are raising their festive glasses to the new year, UK/FCA versions of EMIR, SFTR & MiFIR will come into being.

The following morning when many are nursing sore heads, the ESMA or EU-27 countries versions of these three regulations will similarly be facing the hangover of being greatly diminished and disrupted by the departure of Britannia. 28 minus one might not seem a big margin but its hard to overstate the contribution of the UK financial markets in the European context. With all due respect London is more comparable to New York or Tokyo, than say Paris, Frankfurt or Madrid.

Infantile problems

Phases 1 & 2 of SFTR went live earlier this month so its basically a newborn, screaming a lot and causing sleepless nights. Phase 3 goes lives in October. By December SFTR is a toddler at best. Many firms will still be busy with early remediation items and bedding down the controls, data and processes around SFTR. But nonetheless it will be split into UK-SFTR and EU-SFTR and many of those firms will need to adapt to a new landscape.

The Trade Repositories will offer separate UK and EU TR businesses. Each with separate connectivity, onboarding, reports and so on. The regulation itself insists upon Operational Separation so the firms running the TRs have no choice but to separate them out. Adapting your brand new reporting solution to start sending some transaction reports to a different TR and integrating all the responses and reports back from the new TR is a considerable undertaking. Especially for the firms that have yet to catch their breath from the October phase going live.

The EMIR regulation also gets split into European EMIR and UKMIR. Ok I might have made that last bit up and UK-EMIR or FCA-EMIR is more accurate nomenclature for the UK slice. But in these crazy times Im not sure Id fully rule out the UK tabloids campaigning to kick the E out of our sovereign Market Infrastructure Regulation.

Splitting their EMIR reporting into two versions is slightly less fraught for the reporting firms compared to SFTR, as EMIR is a much more mature regulation. But as well as separate UK/EU Trade Repositories, connectivity and so forth there are other challenges to consider. What about the impact on Delegated Reporting for firms either offering a delegated service or firms utilizing such a service? What about the explicit permissions that was implemented earlier this year? Firms need to ensure they have the appropriate explicit permissions at each TR for the appropriate clients.

Fitting in the REFIT

And what about the EMIR REFITs introduction of Mandatory Delegated Reporting which, as of last month, means the FC (Bank or large dealer) selling OTC derivatives to an NFC- (small non-financial firm below the clearing threshold) has a mandatory obligation to report on behalf of the smaller firm. This was introduced to make the burden on the smaller firms more appropriate. But what happens when the Bank/Dealer finds themselves on a different EMIR jurisdiction to their NFC- client? For example, a London based bank facing a small continental based manufacturing company where the bank falls under the UK-EMIR and their client falls under the EU-EMIR. The mandatory element is gone but the desire to service the client surely remains.

The REFIT is also very much an inflight initiative with many more changes coming including potentially new fields and the introduction of an ISO 20022 schema that Ive been predicting for the lastfour years. On the 1st of January 2021 the EU & UK versions of EMIR will be essentially carbon copies of each other. But each jurisdiction has the potential to diverge and any of the many firms caught with obligations to report to both will need to deal with any divergence. The REFIT is the most obvious example of potential divergence but it only takes an update to the ESMA EMIR Q&As, the ESMA validation rules or the FCA to publish its own guidance and the two versions will be branching off in different directions. There is a slight possibility the FCA and ESMA try to collaborate and agree any changes in common but that looks like a slim chance currently.

The Cheeseboard

And last but by no means least there is the MiFIR regulation or rather the reporting components of the MiFID 2 regulation. The Brexit cheese wire will split this regulation into UK cheddar and EU mozzarella slices. Under MiFIR Transaction Reporting, firms have the option of reporting directly to their home country regulator or reporting via an Approved Reporting Mechanism (ARM).

This reporting directly to the home regulator will alleviate a lot of the disruption to MiFIR reporting firms. However, the ARMs and the firms using them are impacted similarly to the TRs under EMIR & SFTR and in order to provide ARM services for EU firms the ARM needs to be located within an EU country. Many of the ARMs will need to split their offerings into a UK based one and an EU based one.

Anyone familiar with MiFIR reporting will also be aware that firms are dependent on data aggregated by the various regulators across the EU and published by ESMA. For example the Financial Instrument Reference Data (FIRDs) or Financial Instrument Transparency System (FITS) data which ESMA is mandated to publish are key inputs into firms MiFIR reporting. Brexit impacts a few things here. Firstly, the UK data that currently feeds into this system will end and needs decoupled. Secondly the FCA needs to start publishing the UK only version of this data to support UK firms with their UK-MiFIR reporting obligations. The firms themselves need to adapt and configure their systems appropriately for the new data feeds landscape.

And thats just the summary

All the issues mentioned above are the simplified big picture items. In a globalised world with the European financial infrastructure so closely interlinked, the reality will be a lot more complicated for most firms. Very few of the medium to bigger sized firms will have the luxury of falling neatly into UK regulations or EU regulations. The majority will need to deal with both after the Brexit bifurcation.

Im frankly curious why this topic is not getting more coverage. Part of me wonders if some firms are in denial, given how much work and expenditure went into preparing for the previous 2019 March 29th date. [Though I still think the go-live date of April 1st 2019 is the more apt date for that one]. Is there a danger that having put so much work into something that didnt happen that firms are awaiting another Hail Mary event to postpone the pain? Or is it more a case that the heavy lifting was done for the previous deadline and firms are simply dusting down the previous plans and updating them?

Regardless, its time to start discussing the B word again. And no, I dont mean Boris!

The rest is here:

From the C to the B - Putting the B back in Brexit - Finextra

Brexit Tears: A pithy political collection of images and clever wordplay – The National

BREXIT Tears is published by Kettillonia, the small press run by the novelist James Robertson. I wrote about Robertsons novels in The National in an essay called Pushing boundaries (June 10, 2019).

Brexit Tears pushes boundaries of a different kind from those encountered in Robertsons novels.

Its a collection of images by Calum Colvin, the artist and professor of Fine Art Photography at the University of Dundee, along with a series of epigrammatic puns by Robert Crawford, the poet and professor of Modern Scottish Literature at St Andrews University.

Words and images talk to each other through forceful but ambiguous meanings. The words themselves engage ambiguity while emphasising the value of judgment. We can enjoy the playfulness, but they also sustain protest and lament, both angry and determined.

The work is resigned: there is no sentimental wishfulness about what we have failed to prevent (at least, so far, in Scotland), but there is also a sense of why we need to keep resisting it. The lament is there in the title: tears are being shed, but the sheer tearing away, the violence in the word tears (whats being torn) is registered as well.

The book is beautifully produced, on silk art paper, with bold upper case lettering and brightly coloured, sharp and vivid pictures. But the cover, white letters on a black background, is as stark and decisive as a headstone. Consider a few examples of the texts.

LEAVE.CON

ITS impact is instantaneous and should need no further comment. However, as the great American poet William Carlos Williams once said, You should never explain a poem, but it always helps.

Were surely all or almost all of us aware of email addresses that end in dotcom or literally .com and its easy to mistake the m sound for an n sound, so you might look twice before you see what should be obvious.

And thats how con-tricks work. Con as in confidence: the trick is to seduce you into having confidence in something you should be sceptical about, that you should not trust for a moment for a moment is all it takes. Brexit is surely the biggest Leave con-trick of them all (Like Better Together answer: Stronger Apart).

The letters on the page pun and provoke, back and forth, covering years of Westminster government ineptitude, malevolent self-servicing intention, and skilful manipulation (because it has operated effectively). The meanings the letters construct employ all these things and more.

Ali Smith once said she grew up with an appetite for reading everything she could see, the side of a cornflakes packet, the side of a pencil, the side of a bus. If only more people could have read the side of a bus, truthfully.

SCOTTISH LABOUR PAINS

AN interface: Scottish Labour and labour pains: two pairs of words that should belong in different worlds, you might think. Bring them together and theres a judgment: Scottish Labour pains because its so awful, so evasive of necessary questions, and its history of Unionism has been horrible to see unfolding.

But remember the actual birth of the Labour Party through the potency of the Labour movement, breaking through from the Liberal Party as once was in the 19th century into outright opposition to class privilege and entitlement which the Conservative and Unionist Party stood and still stands for.

Labours formation began with the Scottish Labour Party in 1888, then the Independent Labour Party in 1895, and only then the Labour Party as such in 1906.

WE might recollect the founders, Keir Hardie and RB Cunninghame Graham. In their day, more than 100 years ago, home rule and independence were Labour priorities, to break up the British Empire and its history of exploitation, and to establish rights for working men and women.

Do the three words of the poem suggest even fancifully that a truly Scottish Labour Party might even yet begin to feel its own birth pangs returning? Perhaps a sufficient number of party members believe in Scottish independence to suggest that its possible. If so, it would be a fulfilment of Cunninghame Grahams practical insistence that the Labour movement and the vision of an independent Scotland could only realise something valuable by working together.

BREXIT WITHDRAW ALL AGREEMENT

WITHDRAWAL Agreement is replaced by its opposite meaning, Withdraw All Agreement, which seems no more than a fair description and as pessimistic as you might imagine. Then you might ask how the words connect with the terrifying suggestion in the image.

UNTIED KINGDOM

AND the positive sense of breaking free from an imprisonment, liberation from diminishment and limitation, is surely a positive prospect. But the warning remains.

WAR IS JOHNSON

AND a much larger sense of neither dependence not isolationism is affirmed in the idea of interdependence, which requires both individual nations and internationalism.

ECOSSE YOURE WORTH IT

AND to illustrate that, instead of the insidious lie of the advertising campaign (buy this for the sake of your self-esteem: BECAUSE), we have the understanding that Scotland is multiple, seen through the French language (Ecosse), or implicitly as it might be understood through any number of languages in the world, in its own right, in an international context.

YOUR COUNTRY NEEDS EU

IN her novel Spring, Ali Smith writes: Now what we dont want is Facts. What we want is bewilderment. What we want is repetition. What we want is repetition. What we want is people in power saying the truth is not the truth and We need it not to matter what words mean. And: Were what this countrys needed all along ,were what you need, were what you want.

This book reminds us that we want something else.

Brexit Tears costs 10 (including postage and packing) via PayPal from http://www.kettillonia.co.uk

Payment by cheque is also possible by arrangement with the publisher.

More:

Brexit Tears: A pithy political collection of images and clever wordplay - The National

‘The younger the child, the likelier to find causative gene of infant epilepsy’ – Korea Biomedical Review – Korea Biomedical Review

A research team at Samsung Medical Center has found that the younger the patients age, the higher the probability of finding the causative gene of infant epilepsy.

Epilepsy is a neurological disease caused by a variety of causes. However, it is difficult to find the cause of the outbreak, and hospitals conduct various tests and treatment methods to customize treatment for each patient. In some cases, patients develop epilepsy at a very young age, despite their brain MRI test results coming back normal. There remain high unmet needs for a diagnosis to establish the cause.

To resolve the issue, the team, led by Professors Lee Ji-won and Lee Ji-hoon, conducted a genetic panel test using next-generation sequencing on 116 patients under two years of age diagnosed with epilepsy despite having a normal brain MRI.

As a result of the study, the probability of finding the cause gene through genetic panel examination was 34.5 percent for patients under two years of age, 39.6 percent for those under one year old, and 50 percent for babies under six months old.

Until now, it was common for patients, who had epilepsy despite having a normal brain MRI, to receive antiepileptic drugs, the team said. Based on the results of this study, however, we think we have paved the way for selecting an appropriate drug according to the mutation of the causal gene.

In an additional study involving 13 benign rolandic epilepsy patients, the researchers could also diagnose the patients early and quickly provide optimal drugs, it added.

Although more than 50 percent of patients have yet to find the cause of their disease, the team expects to find more causal genes through the ongoing familial genome research, Professor Lee Ji-won said. To establish effective customized treatments, research is underway to produce a cell model that expresses the phenotype of a patient whose causative gene has been identified and screen the therapeutic agent.

Professor Lee Ji-hoon also said, Identifying the genes that cause epilepsy through the diagnostic capabilities of pediatrics clinicians can be a crucial aid in selecting therapeutic drugs, allowing doctors to predict to some extent what prognosis the young patients will show as they grow up.

Molecular Genetics & Genomic Medicine has published the results of the study.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

See more here:

'The younger the child, the likelier to find causative gene of infant epilepsy' - Korea Biomedical Review - Korea Biomedical Review

Known genes associated with male infertility doubled – BioNews

3 August 2020

Thirty-three genes associated with male infertility have been identified through a 'genomics-first' approach to understanding the condition.

Researchers from the King Faisal Specialist Hospital and Research Centre in Saudi Arabia used exomesequencing, a method for sequencingall the protein-coding regions of genesin a genome, to establish a genetic basis for infertility in male patients. It is hoped that a more complete understanding of the molecularbiology behind male infertility, alongside greater application of genomic medicine, will lead to improvements in treatment and diagnosis.

'Male factors account for nearly half of infertility caseswith nearly seven percent of the male population estimated to suffer from infertility' the authors reported in the journal Genetics in Medicine. 'However, current estimates of the contribution of genetics to male infertility (15 percent) suffer from the lack of comprehensive genomic analysis in large cohorts.'

From a non-selected sample of 285 infertile male patients, 69 (24.2 percent) were suspected of displaying a monogenic form of male infertility, meaning that it was caused by a defect in a single gene. Over 400 genes have already been associated with male infertility in mouse models, suggesting that that the monogenic contribution in humans has been significantly underestimated.

The current standard method for diagnosing the cause of male infertility involves screening for chromosomal aberrations, such as Y-chromosome micro-deletions too small to spot by karyotype. However, this technique has a low diagnostic yield, and aberrations were only identified in 30 (10.5 percent) of the patients included in the study.

Of the 285 patients included in the study, 237 presented with non-obstructive azoospermia a failure to make sperm resulting in no sperm in the ejaculate. The remaining 48 patients displayed severe oligospermia, characterised by a sperm count lower than one million sperm per millilitre. An identical number of fertile men were recruited to the study as controls.

'The 33 candidate genes we identified in this study represents by far the largest number of male infertility genes discovered by a single study,' Dr Fowzan Alkuraya, the principal clinical scientist behind the study toldGenomeWeb. 'There are only around 40 genes linked to non-obstructive azoospermia in humans. Thus, our study nearly doubles the genes linked to this phenotype.'

These candidate genes were also selected and verified based on known biological roles in male germ celldevelopment, as well as from compatible mouse models. Three of these genes were deemed as having 'strong evidence' of a connection to male infertility in humans, based on evidence from mouse models, as well as displaying independent variants in multiple unrelated patients.

The scientists are hopeful that these results will encourage further research dissecting the molecular basis of male infertility, as well as the development of future therapies and methods to improve its diagnosis and management.

Link:

Known genes associated with male infertility doubled - BioNews

Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) – Business…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 for the treatment of nonalcoholic steatohepatitis (NASH). The Company plans to initiate a Phase 1 study in late 2020, upon obtaining MHRA approval.

We are excited to advance our ALN-HSD program to the clinic in partnership with Regeneron, particularly given the mass prevalence and high unmet need in NASH, a progressive disease associated with high morbidity and mortality. Given the genetic validation of the target, we believe ALN-HSD has the potential to change the course of this serious and potentially life-threatening disease for which there are currently no approved pharmacologic treatment options, said David Erbe, Ph.D., Senior Distinguished Investigator, Program Leader, ALN-HSD program at Alnylam. Pending feedback from the MHRA, we look forward to initiating the Phase 1 study to evaluate the safety and preliminary pharmacodynamic activity of ALN-HSD in healthy volunteers and patients with NASH.

About ALN-HSD

ALN-HSD is an investigational, subcutaneously administered RNAi therapeutic targeting HSD17B13 in development in collaboration with Regeneron Pharmaceuticals for the treatment of nonalcoholic steatohepatitis. ALN-HSD utilizes Alnylam's Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-conjugate technology, which enables subcutaneous dosing with increased selectivity and a wide therapeutic index. The safety and efficacy of ALN-HSD have not been evaluated by the FDA, EMA or any other health authority.

About NASH

Nonalcoholic steatohepatitis (NASH) is a highly prevalent chronic liver disease in which inflammation and liver cell injury are caused by accumulation of hepatic fat. NASH is a subset of a group of conditions called nonalcoholic fatty liver disease (NAFLD) that can lead to progressive fibrosis, cirrhosis, and hepatocellular carcinoma. Comorbidities include obesity, metabolic syndrome, and type 2 diabetes. Approximately 16 million people in the US live with NASH, with prevalence of the disease increasing due to rising rates of obesity. NASH is projected to be the leading indication for liver transplants in developed countries within the next 10 years. There are currently no approved medical therapies for NASH.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of todays medicines by potently silencing messenger RNA (mRNA) the genetic precursors that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylams commercial RNAi therapeutic products are ONPATTRO (patisiran), approved in the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI (givosiran), approved in the U.S., EU, and Brazil. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit http://www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

Alnylam Forward-Looking Statements

Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, the potential of investigational RNAi therapeutics, in particular ALN-HSD, Alnylam's filing of a CTA for ALN-HSD and its expectations regarding the anticipated timing for initiation of a Phase 1 study of ALN-HSD, and expectations regarding the continued execution on its Alnylam 2020 guidance for the advancement and commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or a future pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by Alnylam products, or in patient enrollment in clinical trials, potential supply chain disruptions, and other potential impacts to Alnylams business, the effectiveness or timeliness of steps taken by Alnylam to mitigate the impact of the pandemic, and Alnylams ability to execute business continuity plans to address disruptions caused by the COVID-19 or a future pandemic; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all; actions or advice of regulatory agencies, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing; delays, interruptions or failures in the manufacture and supply of its product candidates, including ALN-HSD, or its marketed products; obtaining, maintaining and protecting intellectual property; intellectual property matters including potential patent litigation relating to its platform, products or product candidates; obtaining regulatory approval for its product candidates, including ALN-HSD, and maintaining regulatory approval and obtaining pricing and reimbursement for its products, including ONPATTRO and GIVLAARI; progress in continuing to establish a commercial and ex-United States infrastructure; successfully launching, marketing and selling its approved products globally, including ONPATTRO and GIVLAARI, and achieving net product revenues for ONPATTRO within its revised expected range during 2020; Alnylams ability to successfully expand the indication for ONPATTRO in the future; competition from others using technology similar to Alnylam's and others developing products for similar uses; Alnylam's ability to manage its growth and operating expenses within the ranges of guidance provided by Alnylam through the implementation of further discipline in operations to moderate spend and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylams ability to establish and maintain strategic business alliances and new business initiatives, including completing an agreement for funding by Blackstone of certain R&D activities for vutrisiran and ALN-AGT; Alnylam's dependence on third parties, including Regeneron, for development, manufacture and distribution of certain products, including eye and CNS products, Ironwood, for assistance with the education about and promotion of GIVLAARI, and Vir for the development of ALN-COV and other potential RNAi therapeutics targeting SARS-CoV-2 and host factors for SARS-CoV-2; the outcome of litigation; the risk of government investigations; and unexpected expenditures; as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

ALN-HSD has not been evaluated by the FDA, EMA, or any other regulatory authority and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

See the original post here:

Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) - Business...

Cancer drug is first therapy to emerge from 23andMe-GSK deal – STAT – STAT

The pharmaceutical giant GlaxoSmithKline is starting human trials of the first medicine, a cancer drug, that has emerged from its two-year-old collaboration with consumer genetics firm 23andMe.

The novel partnership focuses on using 23andMes massive genetic database, composed of the test results and self-reported health data from 12 million consumers who have taken its tests to learn about their ancestry and a smattering of disease-related genes, and who have said their samples could be used in research. GSK uses the database to try and validate genes and proteins that could be what researchers call targets for new drugs that is, the proteins and other molecules whose functions medicines block or otherwise change.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Visit link:

Cancer drug is first therapy to emerge from 23andMe-GSK deal - STAT - STAT

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer – OncLive

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Huma Q. Rana, MD, MPH, anassistant professor of medicine at Harvard Medical School andclinical directorofCancer Genetics and Prevention at Dana-Farber Cancer Institute, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

There are increasing indications for germline genetic testing in prostate cancer, says Rana. Through several clinical studies, the field has recognized that there is a high prevalence of inherited mutations among men with advanced prostate cancers, and this could have significant implications on treatment. Men with advanced prostate cancer, particularly those with underlying mutations in genes such asBRCA2, are known to have poor outcomes, says Rana. Therefore, it is important to identify these men and make matched targeted therapy available to them and their oncologists.

In recognizing that prostate cancer is a very common disease and that traditional germline genetic testing would be very difficult to implementpotentially overwhelming already strained systems for genetic testinga randomized controlled trialwas conducted. In the trial, investigators compared the effectiveness of a short videothat focused on the educational components of a genetic counseling visit with in-person genetic counseling for men with potentially lethal prostate cancers, concludes Rana.

Link:

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer - OncLive

Metastatic Lung Cancer Study Finds That Bionano’s Saphyr Outperforms NGS for the Detection of Structural Variants – GlobeNewswire

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first study to utilize its genome imaging system, Saphyr, for the analysis of structural variants (SVs) in lung cancer and metastases. The study, published in Translational Lung Cancer Research by a team of scientists from Fudan University Shanghai Cancer Center and Shanghai Medical College, analyzed SVs using both short-read next-generation sequencing technology (NGS) and Bionanos Saphyr system on a primary lung squamous cell carcinoma sample, and on matched metastases from lymph node and pulmonary vein. The study showed that Saphyr outperformed NGS-based methods in the detection of structural variants to characterize the genetic heterogeneity between the primary tumor and the matched metastases.

Of 1026 large SVs detected on average by Saphyr in each of the tumor types, the NGS-based methods failed to detect an average of 77%. Saphyr identified 52 SVs shared between the metastases, while no shared SVs were found by NGS-based methods.

The study authors stated that Saphyr is more capable of detecting large and complex SVs, without the computational and bioinformatic challenges that come with SV calling from NGS data. They found that like with point mutations and small insertions/deletions detected with NGS, SVs make up a large part of tumor heterogeneity. The authors describe that the combination of NGS and Saphyr allowed for a more comprehensive understanding of the variation between primary tumor and metastases, with Saphyr making up for the inability of NGS to detect large SVs.

Erik Holmlin, Ph.D., CEO of Bionano Genomics commented: Researchers are increasingly becoming aware of the importance of genome-wide and unbiased detection of structural variants in cancer and of the severe limitations of NGS-based methods to do so.We are pleased to see this publication showing that Saphyr provided a comprehensive view of structural variants in lung cancer, the most commonly occurring cancer worldwide.Unlike short-read sequencing protocols which start with fragmenting the genomic DNA of the tumor, Bionanos genome imaging analyzes long, intact DNA molecules that are hundreds of thousands to millions of basepairs long, which enables Saphyrto detect structural variants that couldnt be identified before. We believe this study and the growing body of publications on Bionano data show that Saphyr is indispensable for personalized medicine and for furthering the understanding of tumorigenesis and cancer progression.

The study is available at http://tlcr.amegroups.com/article/view/40176/html.

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visitwww.bionanogenomics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyrs capabilities in comparison to NGS-based methods; and Saphyrs potential as an indispensable tool for personalized medicine and furthering understanding of cancer in the medical community. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Kirsten ThomasThe Ruth Group+1 (508) 280-6592kthomas@theruthgroup.com

Originally posted here:

Metastatic Lung Cancer Study Finds That Bionano's Saphyr Outperforms NGS for the Detection of Structural Variants - GlobeNewswire

Health Media in the COVID-19 Era: A mid-wave report – Features – MM&M – Medical Marketing and Media

MM&M first wrote about health medias COVID-19 coverage several thousand news cycles ago on February 3, to be precise. That story concluded with the following paragraph:

So it will continue to fall on health media to alternately inform, educate, soothe and de-escalate. We really need to keep thinking through how we do our jobs in an environment, like this one, where there can be misinformation. If I talk about bat soup, versus be sure to wash your hands, whats going to get more traffic? We need to do more to elevate credible information, even if it sometimes is boring.

That last quote, from WebMD chief medical officer Dr. John Whyte, feels prescient with the benefit of hindsight. Sporadic bursts of overcaution notwithstanding, health media publications and commentators embraced their elevation mission. Drowning out the deniers and grifters wasnt always easy, but nearly every health media organization attacked the task with insight and empathy. In doing so, they elevated the level of understanding and, in all likelihood, prevented people from getting sick, or sicker.

For an insider view of the continuing coverage of COVID-19, we asked leaders from a range of media-adjacent organizations to weigh in on social media follows, coverage blind spots and more. The MM&M media panel included: Jack Barrette, CEO and founder of Wego Health; Amy Conway, editor-in-chief of Health; Alexandra Gilson, director, social media at CMI/Compas; Richelle Horn, senior director, marketing at Wego Health; Craig Mait, president and chief revenue officer of Mesmerize; Andrea Palmer, president of Publicis Health Media; Georgette Pascale, founder and CEO of Pascale Communications; Dr. Judith Simmons, managing director of healthcare at Gather and founder of Lion Head Advisors; Cynthia Spitalny, senior director, integrated marketing at Outcome Health; and Whyte. Responses have been lightly edited for length and clarity.

Simmons: Good curation has been key. COVID updates at The New York Times, Johns Hopkins University of Medicine, STAT, Nature Briefing, Science, The COVID Tracking Project, The New England Journal of Medicine, Kaiser Health News and the CDC have kept up with the rapid pace of important information. Current and former officials such as Dr. Anthony Fauci, Dr. Tom Frieden and Andy Slavitt are experienced and valued voices.

Palmer: Times Up Healthcare (@timesuphc) on Twitter. Only 20% of the decision-makers in healthcare are women, which was an issue before the pandemic and will continue to be an issue if we dont advocate in this space. From a media standpoint, its been fascinating to see how brands are embracing platforms such as TikTok to spread helpful messaging, from P&Gs use of influencers to drive the #DistanceDance phenomenon to fitness and athletic companies creating at-home workout challenges.

Whyte: I focus on Twitter, because I find Instagram doesnt provide the ability to have as much dialogue. @GilBashe curates interesting scientific and policy-type articles. @JeromeAdams, the Surgeon Generals personal account, provides a personal perspective as well as succinct advice on managing the pandemic. @DrJenCaudle is an African-American physician who shares very practical advice.

Conway: On Twitter, Angela Rasmussen (@angie_rasmussen) is a Columbia virologist who shares and demystifies the latest news on COVID-19, calls out others for disinformation and promotes diversity and inclusion and manages to do it all with a dose of humor. Craig Spencer (@Craig_A_Spencer) an ER doctor and Director of Global Health at NewYork-Presbyterian/Columbia University Medical Center, has shared what it was like to be on the front lines back in March and if youre looking for guidance on masks, read his A Soliloquy on Masks. Leah Douglas (@leahjdouglas), a reporter for the Food & Environment Reporting Network, has been mapping COVID-19 outbreaks in the food system. The coverage is impressive, fascinating and terrifying.

Pascale: On Instagram, @humansofny and @wetheurban give a realistic approach to who [are] and what is really being affected.

Gilson: Governor Andrew Cuomo has been a voice of authority in this new normal, with New Yorkers being on the frontlines battling the pandemic in its early stages.

Spitalny: With multiple family members and friends working in healthcare, I am a big champion of frontline essential workers. Mask Match, a nonprofit that helps people with spare masks send them directly to healthcare workers on the front lines or donate to replenish their PPE, was something important to elevate.

Mait: We have relied on the CDC to track cases in the U.S. and for information to protect ourselves and our communities. We have also become more active on LinkedIn than ever before, seeking out leaders of similar-sized organizations to ours to see how they are responding to and dealing with the situation.

Barrette: One of my favorites on Facebook is frontline nurse and immunocompromised patient leader MarlaJan Wexler, who cuts through the politics and BS as only a nurse can do.

Whyte: Laurie McGinley at the Washington Post always provides good analysis of important issues. Shes not trying to get clicks. STAT is terrific for a daily morning update. And living in the Washington, D.C. area, I find Bob Cusack and his team at The Hill helps me understand everything happening in DC that may impact me. Its succinct and timely.

Spitalny: It has been interesting to see how mainstream journalists have been covering the innovative ways companies have addressed their business challenges during the pandemic. I have also been listening to a lot more news through podcasts, like NPRs up first and NY Times The Daily. They help prepare me for the day and keep me apprised of topics that may become important to what we message and pursue as an organization.

Palmer: COVID has shown us just how important it is to create content with a consciencecontent that works in service to the people who consume it. Lets elevate voices in the media who are dedicated to truth and facts, like Pien Huang from the Science Desk at NPR. Since the start of the outbreak, she has consistently shared thought-provoking pieces that aim to educate readers.

Conway: Olga Khazns articles for The Atlantic are engrossing and surprising, answering questions you might not even have thought to ask: Why did it take so long for therapists to start seeing clients remotely? Why does Americas sick leave policy work against its workers? Is a socially distanced pool still fun? STATs no-nonsense news reporting by Sharon Begley, Helen Branswell and Andrew Joseph goes deep into the science of COVID-19 but is always readable, engaging and enlightening.

Barrette: Overall, traditional media has pounded us with the latest hours sound bites from experts who themselves are learning real time about this disease. The result is confusion, fear, complacency and desensitized consumers

Gilson: More important than individual voices has been the collective conversation on COVID, stemming from patients and HCPs trying to navigate chronic diseases and cancer which did not let up despite the pandemic monopolizing health conversations. Those patients and their doctors are still in need of critical information, now more than ever, to keep up to date on treatments and recovery in a post-COVID world. Individual voices such as Governor Cuomo and Dr. Fauci will continue to be important in the evolving climate, but Pharma should continue to pay attention to the masses in understanding trends and sentiment within healthcare.

Pascale: Local papers and online sources are covering the news that is real and relevant to you. Sometimes its most helpful to track how things are influencing you locally, in your own backyard.

Simmons: The New York Times has stood out in providing local, national, and global views, reporting on the science, and publishing beautiful data visualizations that have helped make information clear for readers.

Mait: Unfortunately, many of us are avoiding mainstream media and news cable channels as they appear to be adding to the problem by politicizing COVID-19. Weve relied on Andrew Cuomo and Bill de Blasios daily press briefings on TV for updates on COVID-19s progress in New York. We try to listen to the medical professionals giving proper information, like the CDC, Dr. Anthony Fauci and Dr. Sanjay Gupta.

Spitalny: I am most impressed by 17-year-old Avi Schiffmann, the high school web developer who had the foresight to begin tracking COVID-19 in December when it wasnt really a news topic in the United States. His website demonstrates that ingenuity and talent can come from anywhere. Although he was offered up to $8 million from sponsors and has had numerous job offers, he declined all of it; he is adamant about protecting the integrity of the data and the site.

Simmons: Dr. Craig Smith, chair of the Department of Surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center, started writing a series of daily letters that spanned a 50,000-foot overview to the ground level of his hospital. He shared important information with perspective, warmth, context and occasionally poetry. Each letter was a realistic and human assessment of the moment and collectively they have become a narrative of the pandemic.

Palmer: NPRs What Do Coronavirus Racial Disparities Look Like State By State? should be required reading. Its thorough and outlines through visuals and statistics how and why people of color are so disproportionately affected by COVID-19. We need to put this new data into action, creating points of connection and communication where they are missing or ineffective. Moving America in a healthy direction will be about more than combatting the virus effectively; itll be about advancing our society justly and inclusively.

Conway: Some Coronavirus Guidelines, a New Yorker piece by John Kenney published in March, offers helpful guidelines on how to handle the Coronavirus crisisbeginning with the simple dont panic and wash your hands and progressing to the end of the world. Its funny because it pokes fun at the very real escalation of thoughts and fears we were having at the time (and still are!).

Whyte: The reporting in March around the growing mental health epidemic was prescient. I think some people thought it was just anxiety and would go away. But we are seeing how the pandemic is exacerbating mental health issues in those persons already diagnosed, as well as creating new mental health problems in people who never exhibited problems. I give credit to Arianna Huffington and her Thrive platform, which has been sounding the alarm bell from the beginning. The medical community has only recently come around to recognizing the problem.

Spitalny: The personal impact that this pandemic has taken on HCPs has felt overlooked. My husband is a physicians assistant and works at a major hospital, so seeing his day-to-day activity and knowing that other HCPs are probably going through something similar (burnout, cut wages for longer hours, etc.) suggest there are stories that needed to be told that were grittier than just the headline.

Whyte: We dont have an adequate explanation of the data. We report the number of cases and deaths, but we dont focus enough on local infection rates and what they mean. Early on, many cases occurred in clusters in certain counties. That was relevant to know when we talked about containment. We also didnt acknowledge the uncertainty of data, that we were learning as we went along. So we made different recommendations at different times relating to masks and antibody testing. That caused confusion and eroded trust.

Mait: During the last few months, there has been a lack of leadership from the federal government, a lack of a centralized voice with clear messaging and, of course, a lack of scientific data given the novelty of the disease. This disease is something that so clearly should not be politicized, yet it has been. What we need is a real task force with a centralized voice that everyone has access to and that is not politicized. Coverage should focus on the top doctors and what they are doing and saying about COVID-19 and the reasons why.

Simmons: The unprecedented breadth of achievements in six months related to this virus and pandemic. COVID-19 is a totally new disease and when I look back on what has been accomplished in basic science, therapeutics, clinical management, vaccine development, transmission and adjustments in how people live and work in just months its amazing. It matters because we need to use the growing bank of facts and science that we have learned to guide us as we move ahead. We know a lot more now.

Horn: Having had cancer and working so closely with patient leaders, I would like to see more coverage on how people living with chronic health conditions (immunocompromised, genetic disorders, metabolic disorders) should safely, if at all, re-enter society as things begin to open up.

Pascale: People have mistakenly thought this was going to be over by now. We need to continue to put emphasis on what we are doing as we move forward. For example, with my sons basketball camp canceled, we made do by involving him with a mini-camp in the neighborhood. These kinds of things are important to talk about, as they show how people are functioning during this time. Hyperlocal pieces can be helpful, witty and smart, and get people to a better place of understanding.

Conway: The reporting is starting to catch up, but it took a while before there was substantial coverage about how discrimination and disparity play into the pandemic. Because of long-standing inequities, African-Americans, Hispanics and Latinos and American Indians/Alaskan Natives are at increased risk for getting or becoming seriously ill with COVID-19. The LGBTQ+ community already faces discrimination when seeking healthcare and may avoid getting care. Socioeconomic disparity means that children without computers or reliable Wi-Fi are not able to learn online. Workers without paid sick leave or other benefits may put themselves or others into vulnerable situations. The list goes on.

Palmer: We need to make sure that science-based solutions are not being politicized in the news. With the rise of Black Lives Matter, we are now more aware of the social determinants that have led to disproportionate COVID-19 cases in the Black community but we havent heard enough about solutions. Black Americans are 3.5 times more likely to die of COVID-19 than White Americans. That statistic should send shock waves through everyone, and inspire wide-scale behavior change. If individuals arent doing it themselves, its worth asking in our industry how media and marketing can create the impetus for broader institutional change to take place.

Whyte: 1. Data needs to be presented in terms of local infection rates. Everyone isnt a NYC or small town in Wyoming. You need to put the data in context. 2. Stop all the talk about the vaccine, because its just not realistic. Lets have a real discussion around risk and help people understand how to live with the virus. 3. Acknowledge the role of innovation. Despite some problems with testing and mixed results from therapeutics, we had nothing five months ago. The perfect cannot be the enemy of the good.

Simmons: We havent communicated a clear understanding of how the virus is transmitted, how pandemics grow and how one persons actions may affect others. Mask wearing has become politicized, rather than normalized, and that must change. Weve got to keep refreshing peoples knowledge and presenting essential information in all ways across all platforms. This virus is not going away and we will have to adapt to it.

Conway: 1. The importance of improving diversity in the fields of science and medical care. In 2018, just 5% of active doctors in the United States identified as Black or African-American, according to the Association of American Medical Colleges. According to the American Psychological Association and American Psychiatric Association, just 4% of psychologists in the U.S. and 2% of psychiatrists are Black. Having different viewpoints and voices can improve care for all. 2. What are the long-term ramifications for children in terms of socialization, education and overall health and well-being? What services have special-needs children been gettingor more importantly, not gettingduring the pandemic?

Barrette: 1. Share concrete steps that every consumer can take, and specifically how those steps will lessen the suffering caused by the virus *in their area*. For example, if 80% of Bostonians wore masks starting now, you could watch the Red Sox in August. If its just 50%, the season is canceled. 2. Check the facts before publishing anything. If theyre wrong, either dont put them out or correct them. 3. Share more stories of how [US geography here] truly flattened the curve and back it up with data.

Spitalny: Id like to see coverage of how content providers are creating compelling, unbiased information about the benefits of wearing a mask. Id also like to see a full 360-degree look at whats happening in healthcare beyond the explosion of telehealth. Id like to see journalists tackle touchy topics like, for example, if hospitals are losing money because of electives being pushed or on the personal impact of the coronavirus crisis on HCPs in terms of mental health and loan burden. Are these crises within a crisis?

Pascale: 1. Focusing on the positives a bit more would be nice. There has been some good news that hasnt received enough recognition. 2. Reiterating that we still need to be responsible. We need to find a balance in coverage about continuing to take precautions, and how to do so. Repetition builds retention! 3. Collaborating and working together to make things happen quicker, especially scientifically. With more people sharing data when developing drugs, the endpoint can be sped up safely and effectively.

Horn: I would like to see more of an emphasis on preventative care. What are the effects of skipping or delaying appointments, or discontinuing medications? As someone who had her thyroid cancer detected during a normal well visit, I want the media to encourage people to continue to seek care during this time.

Palmer: Talk about a moving target. A little while ago, we were excited about gradual reopening and outdoor dining. By late June, we were seeing around 40,000 new cases a day, with Dr. Fauci warning the sum could rise to 100,000 new cases a day. That said, the media needs to continue focusing on prevention and caution. When this started, we saw a lot of coverage around quick fixes for our stress levels and overall quarantine wellness, such as virtual fitness classes. Now, we know we are in this for the long run, and people need endurance. They need long-term solutions to the mental health challenges were mired in. Coming off COVID-19, we need the media to look at mental health with fresh eyes and future-facing insights.

From the August 01, 2020 Issue of MM&M - Medical Marketing and Media

Read more:

Health Media in the COVID-19 Era: A mid-wave report - Features - MM&M - Medical Marketing and Media

Thousands March in Berlin to Protest Coronavirus Curbs – The New York Times

BERLIN Thousands marched in Berlin on Saturday to protest against measures imposed in Germany to stem the coronavirus pandemic, saying they violated people's rights and freedoms.

The gathering, estimated by police at 17,000, included libertarians, constitutional loyalists and anti-vaccination activists. There was also a small far-right presence with some marchers carrying Germany's black, white and red imperial flag.

Protesters danced and sang "We are free people!" to the tune of rock band Queen's "We Will Rock You". Others marched with placards saying "We are making a noise because you are stealing our freedom!" and "Do think! Don't wear a mask!".

"Our demand is to return to democracy," said one protester who declined to give his name. "The mask that enslaves us must go."

The protests followed a rallying call from Michael Ballweg, an entrepreneur and political outsider who has organised similar rallies in Stuttgart and is running to become mayor of the southwestern city.

Police filed a complaint against the organiser for failing to ensure marchers wore masks and kept their distance. Mainstream politicians criticised the protesters, with Social Democrat co-leader Saskia Esken calling them "covidiots".

"They not only endanger our health, they endanger our successes against the pandemic," tweeted Esken, whose party is Chancellor Angela Merkel's coalition partner.

After Germany's initial success in curbing the pandemic, infections are rising again. More than 200,000 people have caught COVID-19 and more than 9,000 have died from it.

Most people in Germany have respected measures that include wearing face masks in shops, while the government has just imposed mandatory tests for holidaymakers returning from high-risk areas.

But a vocal minority is chafing against the restrictions.

"Only a few scientists around the world who follow the government's lead are heard," said protester Peter Konz. Those who hold different views "are silenced, censored or discredited as defenders of conspiracy theories".

(Reporting by Reuters TV, Writing by Douglas Busvine; Editing by Giles Elgood)

View post:

Thousands March in Berlin to Protest Coronavirus Curbs - The New York Times

Reign of the Nerds – Splice Today

The high schoolers on your street who load up on Mountain Dew and play D&D (Dungeons & Dragons) all night may know more about the political spectrum than their parents.

Gary Gygax and David Armisen created D&D in 1974, the same year Richard Nixon resigned from office. It was a timelike nowwhen questions about the uses and abuses of legal and political power cast shadows over everyday conversations. In a stroke of genius, about which we know very little, Gygax and Armisen organized their fantasy world according to alignments: good, neutral, and evil, respectively. Each alignment was sub-divided further into another three sections: lawful, neutral, and chaotic. Any character (created and impersonated by a human player), and any non-player character (handled by the Dungeon Master or DM), had a designated alignment. This helped the DM and the players figure out how their characters would behave, how theyd interpret the events in each adventure, and how theyd react to each other.

Good and evil are as nebulous in the world of D&D as they are in the real world. In theory, certain characters are always good (soft-spoken healers), others predictably evil (undead sorcerers bent on world domination); in practice, the players usually perceive themselves as good, unless theyre weird. They also tend to believe that anything they want to stab is evil. Neutral, a bizarre category that borrowed heavily from J. R. R. Tolkiens charmingly indifferent minor characters, continues to baffle players ages 11+ to this day. All we can say for sure is that it has something to do with caring more about nature than people. D&D came out just two years after Arne Naess and George Sessions coined the term deep ecology. Apparently, Gygax and Armisen were listening. (That said, its too bad that Naess and Sessions didnt invent a role-playing game of their own, set on a planet imperiled by climate change and industrial pollution.)

Lets table good and evil, for the time being, and replace them with right and left. Im sure those strike you as slippery categories. Sometimes they get cleared up by the stands people take on individual issues, like abortion rights. Other times, theres a historical precedent: calling Communism leftism, for example, or assigning libertarianism to the Right. Youve probably heard someone say that the Left and Right meet at the extremes, which sounds counterintuitive and profound, but actually just muddies the waters. Former leftists sometimes veer to the right. Thats what happened to Benito Mussolini, William Wordsworth, and many former Communists in America. By the same token, I can give you countless examples of religious conversions. But the fact that a Lutheran in Minnesota has recently become Muslim doesnt mean Christianity and Islam meet at the extremes. People are fickle. Nonetheless our idea of a political Left and a political Right endure.

Contra Crispin Sartwell, who writes (both here and elsewhere) about this issue quite frequently, I have no trouble defining these opposing sides. People on the left are, as we say, progressives. They believe in the unfinished project of making society better in unprecedented ways. Their opponents on the right are conservative; they uphold the claims of tradition and existing social structures. Neither side is inherently more committed to individual rights. Conservatives believe in all the individual rights they perceive as vital within the traditions they cherish most. Progressives tend to want to extend individual rights, but not at the expense of the common good. For example, theyll happily defend the Endangered Species Act against challenges from individual property-holders, because they believe environmental protections promote the general welfare.

These are not vague distinctions, or prone to sudden eclipses, once you separate each concept from its shifting constituency. They are, instead, fundamental questions of political emphasis. Everyone believes somewhat in tradition, and somewhat in tinkering with the status quo, but individuals path-commit to one or the other in ways that snowball into lasting affiliations. How do we make sense of the way people on both sides of the spectrum disagree amongst themselves? Is everyone on the Right bound to support Donald Trump? Is everyone on the Left secretly hoping the nanny state will intervene and solve all their problems? This is where politics needs to borrow from D&D.

Lets say your alignment is Lawful Conservative. That means you believe in the rule of law pretty unconditionally. You may believe in the democratic process, and the right of a people to change the laws that govern thembut that doesnt mean you support tossing laws aside when they become inconvenient. Youre a consistent voter. You support laws that defend traditional institutionslike tax exemptions for religious organizationsand oppose laws you perceive as disruptive to the normal functioning of society. The American evangelical movement is lawful and conservative. So are Wall Street and most police officers. J. R. R. Tolkien is extremely biased in favor of legal precedents and comfortable observances; youll notice, in his novels, that every rebellious act of good is based on restoring lost traditions, reinstating monarchs, and upholding the placid, cyclical existence of the Hobbits. It isnt bizarre to range fascism among right-wing movements, either; fascists are nationalistic (conservative), nostalgic (conservative), and pro-industry (which, at this point, is conservative too). The Nazi state didnt cause trouble for loyal German families who believed in Jesus Christ. On the contrary: it did everything possible to empower their success.

The biggest difference between a lawful conservative and a lawful progressive is the way they talk and vote. Their actual lifestyles tend to converge, which is why interns from both parties love to hang out together in Washington bars. Extreme political thinkers, who want to overthrow the government, are still either right-wing or left-wing: theyre either trying something altogether new, or theyre trying to restore a tarnished Golden Age. Though a few decaying remnants of pastoral fictionsparticularly natural law and natural rightsstill carry some weight with the Left, most thoughtful leftists reject the notion of a pre-existing Golden Age. Most progressives with a college education can tell you that Jefferson owned slaves, and that the Greeks oppressed their women, and may well continue talking in this vein for a long time if you make the mistake of buying them a drink.

The sunset gleam of the pastoral is particularly discernible in the fantasies of anarchists, our apostles of chaotic leftism. Anarchists arent libertarians; they arent close to libertarians, although the two ideologies sometimes become bedfellows. Anarchists believe in voluntary associations among people: cooperative businesses, direct local democracy, and protecting individual rights through a moral consensus. This is pretty much a distant horizon, in terms of whats even been tried among human beings. Anarchists dont mind that; they rightfully consider themselves idealistic. Libertarians, on the other hand, are chaos-loving conservatives who simply dont trust the law. Theyd rather allow people to do all kinds of damn foolishness than try to restrain them. Libertarians dont think about corporate power often, although they deplore most legislation that increases it; to anarchists, meanwhile, corporations and governments are part of one interdependent, oppressive system of hierarchies. At its base, this speaks to a fundamental difference between two incompatible political visions: doing away with corporate hierarchies, in the name of progress, or assigning them a placeas limited, private institutionswithin a natural and timeless order.

Neutrality, on the Right and Left, is harder to pin down but no less important. Here are two very different misdemeanors: smoking marijuana, and driving faster than the speed limit. Intuitively, you probably see the first as vaguely progressive, the second as conservative. Thats truebut why? Because of the way people justify their acts. Marijuana, thanks to the Beats and the hippies and the Rastafarians, has a certain reformist cachet. It will expand your mind. Its an experiment. Its a spiritual practice. Its an analgesic, relieves anxiety, and could be used to treat other disorders as wellif the government would just stop making it so illegal. The marijuana lobby is basically neutral in disposition: legalize it if you can, hide it if you cant. Theyll take the laws cooperation, when they can get it, but they wont take the systems no for an answer. Either way, their ideological justifications are usually based on claims that pot makes people, and society, somehow better off. Thats progressive.

Speeding, on the other hand, isnt a religious experience, except in certain novels by J. G. Ballard and Jack Kerouac. Its personally motivated and privately justified: why is this road 30 mph? I want to drive it faster. We think to ourselves, I know how fast you can go on this roadknow it better than the bureaucrats in the government. Is that libertarian thinking? Almost. But then the person behind you, in the vintage convertible, comes alongside to pass. On a double-laned road. When you were already going as fast as anyone should go. I hope they get nabbed, you mutter. So much for libertarianism, eh? Taking a neutral stance towards the law implies that the ends always justify the means. Protest, if you can get the police to listen; riot, if you cant. Lobby for loopholes in your taxes and emissions; meanwhile, dump what you mustright into the river. In the long run, playing the law for a sucker isnt really politics at all; as Immanual Kant first argued, its a small (but significant) tearing of the social contract. But its also something we all do, in bigger or smaller ways, from time to timeand such sabotage becomes a sunk cost for any institution we depend on.

Incidentally, if you want to see the conservative version of this, watch the Fast and the Furious movies. Every film is another assembly line for convenient, nostalgic, made-to-fit neutrality, usually in the name of family. A cop goes undercover to bust an illegal drag racing ring. Then the cop becomes an illegal drag racer. Then he and his buddies protect their families against gangsters. Which means joining forces with the cops. Until theyre forced to go rogue. But not really. The reversals get dizzying, and its a goofy undertaking from the first five minutes on, but the series acrobatic, blas agnosticism towards the law ought to win some kind of prize: an award for cognitive dissonance turned all the way to 11.

As noted at the beginning, the kids who play D&D learn this stuff by heart. They know all about the chaotic goblin who resents his chieftain, and the lawful sheriff who takes our heroes into custody because the king hadnt signed off on their escapade. (He also thanks them, surreptitiously, for saving the townsfolk.) They know about the neutral druids who currently baffle Winterfrosts poachers and its licensed hunters, and wouldnt let a poor woodsman take one small wyvern home to eat. But something happens to these prodigies of political understanding. They put away childish things and unlearn the truth about alignments. They start insisting that all left-wing scholars are authoritarians at heart, or claiming that Republicans are corrupt by nature. They accuse libertarians of anarchism, anarchists of Communism, and socialism... well, they accuse socialism of making them wear a mask when they go outside. The political spectrum is more like a circle, really, they declare. Thats why Im an Independent. And the clarity we were granted, thanks to a lucky, lucid moment on the part of Gygax and Armisen, goes back on the shelf. Maybe those handbooks are still there, waiting to be recognized for unriddling our politics vis--vis the lawalongside the experiments that made us a better nation, and the traditions we try to keep from wobbling; things which, taken together, comprise our rightful vocation as Americans.

Read the rest here:

Reign of the Nerds - Splice Today

Comet of the Week: 67P/Churyomov-Gerasimenko – RocketSTEM

A sketch I made of Comet 67Ps visual appearance through a 20-cm telescope on December 24, 1982.Perihelion: 2015 August 13.08, q = 1.243 AU

There have been a handful of occasions throughout recent history when someone has discovered a comet while looking for, or examining, another one. Such an incident happened in late 1969 in the former Soviet Union, when on September 11 Svetlana Gerasimenko with the Alma Ata Observatory (in what is present-day Kazakhstan) took photographs of Comet 32P/Comas Sola. Klim Churyumov, then with the Kiev Observatory, performed the astrometric measurements of what he believed was that comet, but a month later realized that the positions were far off. Upon re-examining the photographs he found that he had in fact measured a previously-unknown comet that was some two magnitudes brighter than Comet Comas Sola (that was also on the photographs).

The newly-discovered Comet Churyumov-Gerasimenko was found to have an approximate orbital period of 6.6 years. It has been recovered on every return since then, and during the 1982 return, which took place under very favorable viewing geometry, it reached 9th magnitude and I was able to detect it with binoculars. It also exhibited a distinct dust tail which on one occasion I measured as being 20 arcminutes long visually.

Comet 67P achieved fame in the mid-2000s when it was selected as the destination for ESAs ambitious Rosetta mission. Rosetta had originally been scheduled for launch in January 2003 with its destination being Comet 46P/Wirtanen, however a failure of the Ariane 5 launch rocket a month earlier grounded all flights of that vehicle until the necessary failure analysis could be conducted. Comet 67P was accordingly chosen as the new destination.

Rosetta was successfully launched from Kourou, French Guiana on March 2, 2004. Over the next 5 years it performed three gravity-assist flybys of Earth as well as a very close gravity-assist flyby of Mars, and as discussed in a previous Special Topics presentation it also performed flybys of the main-belt asteroid (2867) Steins in September 2008 and the larger main-belt asteroid (21) Lutetia in July 2010. Not too long after the Lutetia encounter Rosetta was placed in a state of hibernation, from which it was awoken in January 2014. From there it made its final approach to Comet 67P, arriving there on August 6 of that year, and after various maneuvers, it successfully entered orbit around the comets nucleus a month later.

The approach photographs showed that the comets nucleus is made up of two discrete hemispheres, one distinctly larger than the other, making it a contact binary similar to several of the near-Earth asteroids that have been successfully radar-imaged (and also the Kuiper Belt object (486958) Arrokoth that was visited by the New Horizons mission at the beginning of 2019). The evidence that has been collected suggests that the two hemispheres were at one time two separate objects that collided and stuck together a long time ago and based upon the various other objects that exhibit such a structure it would appear that this is a relatively common occurrence amongst the small bodies of our solar system.

At the time of Rosettas arrival, Comet 67P was a full year away from perihelion passage, and the overall rationale for the mission was to examine the comet as it approached perihelion and became active, and then as it began to shut down as it receded from perihelion. With an onboard complement of eleven scientific instruments Rosetta was able to conduct numerous scientific studies throughout that time, and among its findings were numerous organic compounds, including four for the first time (one of these being acetone), a deuterium-to-hydrogen ratio in its water that is three times higher than that in Earths seawater the significance of these findings being part of the subject of a future Special Topics presentation large amounts of free oxygen (which was quite unexpected), a lack of a magnetic field, and the appearances of numerous sinkholes and the crumbling of cliffs as the comets activity proceeded.

Rosetta also carried a separate probe, Philae, that was designed to soft-land upon the comets nucleus. Rosetta released Philae on November 12, 2014, for a seven-hour descent to the comets surface, but unfortunately, the planned anchoring system failed and Philae bounced twice before coming to rest, apparently on its side in a hole next to some high cliffs. It was nevertheless able to carry out various scientific observations during the 60 hours before its battery power ran out, and while the cliffs were apparently made of a rather porous material, Philaes drilling hammer broke after a few minutes, indicating that the ground underneath it was very hard, either rock or solid ice. After its batteries ran out contact with Philae was lost; meanwhile, there was hope that a better sun angle later in the mission might allow for the batteries to be recharged to an extent, and in fact, contact was briefly restored on a couple of occasions in June and July 2015 but unfortunately not long enough for any significant data transmission.

Rosettas mission was formally scheduled to end at the end of 2015, however, before that time the mission was extended until the end of September 2016, i.e., a full year after the comets perihelion passage and two full years after the spacecrafts arrival. As that time approached Rosetta was placed into progressively lower orbits, and on September 2 it successfully photographed Philae, on its side, and wedged against a large overhanging cliff. On September 30 Rosetta touched down upon the comets surface, and contact was terminated.

The large collection of data collected by Rosetta during the two years it spent orbiting Comet Churyumov-Gerasimenko is still being analyzed and will continue to be for some time yet to come. Just last year, for example, a Spanish amateur astronomer, Jacint Roger, was examining Rosetta images when he found a four-meter-wide moon in images that had been taken on October 21, 2015. This Churyumoon, as it was dubbed, was not a permanent feature, but did orbit the nucleus at a distance of 2 to 3 km for the next two days before disappearing.

The viewing geometry during Comet 67Ps 2015 return to perihelion was not especially favorable, with the comet for the most part remaining at a moderately low elongation in the morning sky and reaching a peak brightness of about 12th magnitude. Meanwhile, although it wont have the fanfare that accompanied this recent return, the comets next return, in 2021, is a very favorable one, similar to that of 1982. It passes through perihelion on November 2 and is closest to Earth (0.42 AU) less than two weeks later, and once again should reach a peak brightness around 9th magnitude.

This Week in History Special Topic Free PDF Download Glossary

See the original post:

Comet of the Week: 67P/Churyomov-Gerasimenko - RocketSTEM

How to spot Comet NEOWISE before it disappears for thousands of years – PBS NewsHour

Theres still a little bit of time to catch a glimpse of a newly discovered comet as it blazes across the night sky, especially if you have binoculars or a telescope handy.

C/2020 F3 NEOWISE, also called Comet NEOWISE, was first spotted in late March of this year by NASAs Near-Earth Object Wide-field Infrared Survey Explorer (NEOWISE) mission. According to NASA, the comets nucleus is about 3 miles in diameter and composed of dust, rock and frozen gases left over from the birth of our solar system around 4.6 billion years ago.

When comets near our sun, the increasing heat creates a coma, or a kind of atmosphere composed of particles and gases that surrounds the nucleus. A combination of solar wind and the pressure of sunlight can blow some of that atmosphere away from the comet, forming two tails one made of ions, and another made of dust that can extend in the opposite direction of the sun for millions of miles. Imaging suggests that Comet NEOWISE could potentially have two ion tails, as well as its dust tail.

Graphic courtesy of NASASpacePlace via Wikimedia Commons.

Joseph Masiero, who serves as NEOWISE deputy principal investigator at NASAs Jet Propulsion Laboratory, said that spotting Comet NEOWISE was exhilarating, particularly given how rare it is for comets that are visible to the naked eye to pass by our planet.

These kinds of celestial events really help remind me how big and wonderful the universe is, and how fortunate I am to get to explore it in these difficult times.

Im pretty sure every astronomer surveying the sky has a secret hope to find the next naked-eye comet, so I feel like our team won the lottery on this, Masiero said. These kinds of celestial events really help remind me how big and wonderful the universe is, and how fortunate I am to get to explore it in these difficult times.

Comet NEOWISE made its closest approach to Earth on July 22 and has grown dimmer and dimmer as it heads back toward the outer reaches of our solar system. But if you want to try your luck over the next few days, find a patch of sky with a minimal amount of light pollution where your view wont be obstructed by trees or buildings.

This graphic marks Comet NEOWISEs trajectory over the next few nights from the perspective of someone stargazing in the Northern Hemisphere. Megan McGrew/PBS NewsHour

Then look to the northwestern sky below and just a bit west of the Big Dipper the comet will be climbing higher above the horizon as the nights wear on. You can also use the Comet NEOWISE app to help you figure out exactly where to look for the comet from your location.

Although you may still be able to spot Comet NEOWISE with your naked eye, a pair of binoculars or a telescope should give you a clearer view. The publication EarthSky also recommends using a high quality camera that can capture the comet with an extended exposure.

If you miss the show this time around, youll just have to wait another 6,800 years or so for Comet NEOWISE to make its way back to Earth.

Comet NEOWISE, also known as C/2020 F3, is seen on July 18, 2020 in Joshua Tree, California. Photo by Daniel Knighton/Getty Images

Read more from the original source:

How to spot Comet NEOWISE before it disappears for thousands of years - PBS NewsHour

Turmeric, apple cider vinegar and other home remedies for psoriasis – TheHealthSite

Psoriasis is an autoimmune condition that causes the immune system to over-produce skin cells. For people suffering from this condition, thick, red, scaly, itchy plaques are a common occurrence. This condition can take a toll on a persons overall quality of life. According to researchers of the Psoriasis Research Unit at Baylor Research Institute in Dallas, there is a need for psoriasis to be viewed as a serious disease affecting the whole body with significant quality of life issues. They say that, in the past, psoriasis was viewed primarily as a cosmetic nuisance that was not thought to extend beyond the obvious plaques apparent on the skin. But with the discovery of multiple genes related to this condition, a better understanding of the immune system responses involved in this disease, and the frequent associations with other serious diseases, it is now clear that psoriasis is a much more complex disease that demands continual monitoring and evaluation by a dermatologist. Also Read - Avoid these foods and drinks if you have psoriasis

This is a debilitating condition, no doubt. But you can deal with the symptoms on your own with a few home remedies. Also Read - 5 effective home remedies to treat psoriasis

This is one of the best natural remedies against psoriasis inflammation. Many experts have conducted research on this subject. Scientists say that application of aloe vera gel can reduce the redness and scaling that comes with psoriasis. You can buy this gel from the market or you can take a fresh aloe vera leaf and take out the get. Just slice the leave and scrap the gel off. Apply this to the affected area daily. Also Read - People with psoriasis can also get joint disease: The connection explained

This can help you get relief from scalp itch, which is so common in people suffering from psoriasis. Go for the organic variety and apply it to your scalp daily. You may dilute the apple cider vinegar with a little water in case it stings. But if your scalp is cracked or bleeding, avoid this treatment as it can make matters worse.

Capsaicin is a substance present in chili peppers. This gives chillies their favour and makes them spicy. If you add this to ointments, it can block nerve endings that transmit pain. It can also help reduce inflammation, redness and scaling. But be careful. It can burn people who have sensitive skin. It is best to consult a doctor before using this.

This can help you get rid of scales and reduce the itching that comes with psoriasis. Just add some to warm water and soaking in it for 15 minutes or so. But sometimes, this can cause dry skin. So be sure to apply a moisturizer after your bath.

This has antiseptic properties that can heal skin related issues. You can use a shampoo that contains tea tree oil to get relief from scalp psoriasis. You can also add a few drops to your bath water. But do an allergic test first. Some people are sensitive to this oil.

This spice has potent anti-inflammatory and antioxidant properties. Curcumin in turmeric is known to alter gene expression. This can reduce flare-ups. Just add it to your daily food. You can also have a one-inch piece of raw turmeric every morning.

Published : July 30, 2020 5:03 pm | Updated:July 31, 2020 10:14 am

Read the original post:

Turmeric, apple cider vinegar and other home remedies for psoriasis - TheHealthSite

Plaque Psoriasis Treatment Market Slated to Grow at an Impressive CAGR of XX% During the Forecast Period 2017 – 2025 – Market Research Correspondent

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

See the rest here:

Plaque Psoriasis Treatment Market Slated to Grow at an Impressive CAGR of XX% During the Forecast Period 2017 - 2025 - Market Research Correspondent

The secret history of Britain’s universities and eugenics – Prospect

Every so often in Britain,eugenicsis accused of making a comeback. Recently, the Black Lives Matter movement has drawn attention to the harmful lasting impact of Britains colonialist figures, shocking those who assumed that white supremacy had been left firmly in the past.

But for those campaigning against the legacy ofeugenicsin higher education, these revelations about the roots of racism were not as surprising. From their perspective, eugenicist views never really disappearedthey had just found a safe havenin somepartsof British universities.

British universities have strong historical ties witheugenics. Sir Francis Galton, a prolific Victorian scientist known to be one of the pioneers ofeugenics, set up a lab at University College London in 1904 and endowed the institution with his personal collection of work, along with funding for the countrys first Chair ofEugenics(the post was renamed, in the sixties, to Professor of Human Genetics.) Until it was finally renamed after Black Lives Matter protests, students at UCL still attended lectureson bio-medical genetic issuesat the Galton Lecture theatre.

In 2018, it was revealed thatasecreteugenicsconference, the London Conference of Intelligence, had been held in a UCL lecture theatre.The event hosted white supremacist academics closely associated with the American alt-right, wrote the London Student.

A UCL internal report on the conference, since made public, show the conference had been attended by fringe academics to policy-interested individuals.In a press statement, UCL said The conferences were booked and paid for as an external event and without our officials being told of the details. They were therefore not approved or endorsed by UCL. The university reassured that they were committed to vigorously combatting racism and sexism in all forms, but also stated that they had a legal obligation to protect free speech on campus, within the law.

The scandal brought attention to UCLs history, and the university launched an inquiry into the history ofeugenicsat the institution. But just before the universitys report was publishedto the public, nine membersof the 16-strong inquiry team refused to sign it, and even argued that the inquiry did not go far enough in a separate set of recommendations. An anonymous member of the committee said: the big issue is not how a member of staff booked a room, but why someone with his views was a member of staff at all.

***

But its not just about one man, or one university.After the Second World War, academics from Cambridge, Oxford and Glasgow were also part of the EugenicsEducation Society, a popular 20thcentury group thatat timescampaigned for sterilisation and marriage restrictions.Universities still memorialise the legacies of famous scientists who made important discoveries but also expressed viewsthat have attracted controversy such asFrancis Crick, who discovered the structure of DNA, andRonald Fisher, a pioneer of modern day statistics.

The home ofeugenicshasnearlyalways been in universities, says David King, director of an independent watchdog organisation Human Genetics Alert. Someacademics tend to believe that all knowledge is good, even if eugenic ideas influence the research, he says:universities are a protected space for these kind of views. Political power has always operated in Britain this way, quietly and below the democratic radar, through conversations between privileged elites, often academics.

However, others disagree. Steve Jones, who was head of UCLs genetics department and former president of the Galton Institute, says that the historical ties these institutions have witheugenicsare discussed openly and extensively. In some ways, the horrors of theeugenicsmovement are what has made biologists cautious about what they are willing to do today says Jones. In the old days those involved knew almost nothing, and were willing to do almost anything; while today we know far more but are much less confident about how we use that information.

Jones argues that there is a crucial difference betweentheperspectives of medical researchers now, compared to those in the era of Galton. Eugenicists set out to change the fate of future generations, whatever the cruelties that might be visited on the people of the day. In contrast, modern genetics tries, although it sometimes fails, to improve the prospects of those alive today Jones says.

But if genetics today hasonly tenuous links toeugenics, why are people worried? A subsection ofresearch, which looks for genetic explanations for complex traits such as intelligence, mental health or personality, has recently gained traction. This field, called sociogenomics,could pave the wayfor a new era of genetic engineering and social stigma. Since the 1960s, dubious journals such asMankind Quarterlyhave been the homes of articles that appear togive backing toscientific racism, classism and ableism.

But now even more respected institutions are dabbling in it. Work linking a persons genetic code to their intelligence, income and educational attainment has been produced by researchers across UK universities, includingKings College London,University of Edinburgh, andGoldsmiths. These studies,one of whichlinks 7-year old childrens test scores with their DNA, would arguably not be out of place at the London Conference of Intelligence. Even the most prestigious academic journals, such asNature Communications, have published studies linking income with genetics. These studies have been cited in reports inMankind Quarterlyto support arguments that Muslimimmigrants have lower IQs than white western Europeans.

Authors from these studies say resultscould helpminimize social disparities in health and well-being, or they could lead toevidence-based, biologically-informededucation policy. But how can linking genes with how much you earn lead tolessinequality? And how would finding tiny unchangeable differences in the DNA of schoolchildren lead to better educational for all, when the biggest drivers of educational achievement are factors like having a safe home, and a comfortableupbringing?

***

The global rise of alt-right populism is to blame for the resurgence ineugenicsresearch, says Professor David Colquhoun, who has worked at UCL for over 40 years. The alt-right give credence to eugenic ideas, and use pseudoscientific genetic theories to support them, he explains. This is documented in scientist Angelina Sainis bookSuperior: The Return of Race Science, where she describes how racists insistently search for biological evidence that they are more special than everyone else. If skin colour cant explain racial inequality, then maybe the structure of our bodies and brains will. If not anatomy, then genes. When this one, too, throws up nothing of value, theyll move onto the next thing, she writes.

Ben van der Merwe is the investigative journalist whodrew attention tothe London Conference of Intelligence at UCL. He believes that universities have beentoo willing to provide a home for these people too. You have a minority of people who are basically cranks, and these individuals (qualified scientists and amateur bloggers) have managed to position themselves as part of the current moral panic over free speech on campus he says. Universities dont appreciate thateugenicsis not a culture war issue over the right to offend.

Universities are further heavily incentivised to hide their history ofeugenics, because many profit from legacy funding from these figures, says a UCL SU Disabled Students Officer, who prefers to remain anonymous. The legacy ofeugenicsseems to pervade inuniversity policies today, which are hostile to students with disabilities and other marginalised groups, they say. Black alumni at UCL have spoken about feeling they were forced out [of the university], and I have no doubt this happens to other groups historically targeted byeugenics. Universities in this country were built from the work of people with many harmful attitudes, says the SU Officer. Students are blocked from finding out about their institutions histories by a lack of accessible information, and an attitude that everything has been fixed now. But it hasnt.

Profit motives and prejudiced policy are not the only factors leading to a culture where eugenicsresearchseems to thrive.Criticising UCLs handling of theeugenicsinquiry, Joe Cain, professor of history of science at UCL,wrote: Excessive deference to managers is one factor. Excessive amounts of discretionary money is another. Crafty people who know how to work the system is a third. Complacent, homogenous, and soft oversight is a fourth.

What should universities do next?UCL have taken important steps, including considering new names for their buildings named after eugenicists, and plan to fund new scholarships to study racism.

David King, who says he has experienced threats and intimidation for speaking up, believes a more extreme approach is needed, in UCL and other centres. He wants places like the Galton Institute to be shut down, and funding for research into genes and intelligence to be removed.

Big science projects cost a lot of money and do not take place unless they are funded King says. There is never enough money to fund all the research that scientists want to do. Science gets stopped every day. So the real question is which science do we want? And who gets to control it?

Go here to read the rest:

The secret history of Britain's universities and eugenics - Prospect